Private joint-stock company Indar insulin producer (Kyiv) saw its net profit decline by 85.7% in July-September 2017 year-over-year, to UAH 4.328 million from UAH 30.68 million.

According to a company report, net revenue fell by 30%, to UAH 142.461 million.

Gross profit declined by 36.4% year-over-year, to UAH 66.545 million.

As reported, in 2016 Indar saw a 3.5-fold rise in net profit, to UAH 29.968 million.

Indar was created under a resolution of the Cabinet of Ministers in 1997 under the aegis of Kyiv meat processing plant. It is a subsidiary of Ukrmedprom with 70.7% of shares in the producer. Luraq Investments Limited (Cyprus) holds 29.3% of shares in the company.

The producer is on the list of state-owned companies of strategic importance for the economy and security of the state.

Indar is a member of the Ukrainian Association of Pharmaceutical Manufacturers, also known as APLU.